Life Science Compliance Update


The full text of this issue is available to our subscribers. If you are a subscriber please log in now. If you are not a subscriber, and would like to become one, please click on the subscribe link or read about all of the benefits a subscription brings by clicking on the Subscribe menu item above.

Jan2015CoverSince January 2009, DOJ has recovered more than $23 billion through False Claims Act cases, with more than $14.8 billion of that amount recovered in cases involving alleged fraud against federal health care programs. In this issue we take a look at several aspects of enforcement activity, including pharmaceutical and device enforcement activity, updates on the physician payments sunshine act, the antitrust landscape for pharmaceutical companies, and a look at international transparency.

In This Issue

ArrowPharmaceutical and Device Enforcement Activity

  • 2014 Settlements Focused on Kickbacks
  • Anti-Kickback Alert: Pharmaceutical Copayment Coupons and Medicare Part D
  • District Court Slashes $9 Billion Punitive Damages to $37 Million in Actos Lawsuit


Update on the Physician Payments Sunshine Act

  • Problems in Open Payments System Roll-Out
  • Sifting Through The Open Payments Data
  • CMS Finalizes Rule Removing Explicit CME Exemption; Most Accredited CME Speaker & Attendee Payments Still Excluded Under Other Sunshine Act Provisions


Antitrust Landscape for Pharmaceutical Companies

  • REMS And The Fast GenericsAct Of 2014
  • New York AG Sues Actavis over “Forced Switching”
  • Pay-for-Delay: FTC Brings Pay-For-Delay Lawsuit, Its First Since the Supreme Court Analyzed the Issue in FTC v. Actavis; AstraZeneca Wins Huge Pay-For-Delay Case Involving Its Nexium Drug


International Transparency

  • EFPIA Disclosure Code – Country-By-Country Code Resource


Menu Title